Shock, Septic Clinical Trial
Official title:
Body Composition Monitor to Quantify Fluid Overload Related to Vascular Leak in Septic Shock Patients
Fluid management in septic shock patients remain a great challenge. Insufficient fluid filling lead to hypovolemia, organ failure and increased death, whereas fluid overload was associated to an increased morbidity and mortality in several studies. Several invasive and non invasive strategies have been developed during the past years to monitor the hemodynamic state of septic shock patients, but no method has been validated to objectively quantify fluid overload in septic shock patients. The Body Composition Monitor (BCM) allow for measurement of total body water (TBW), extracellular water (ECW) and intracellular water (ICW) volumes using bioimpedancemetry. The BCW is daily used in patients who undergo renal dialysis to assess the effectiveness of fluid removal. The BCM has never been validated in septic shock patients. The aim of the study is to investigate the accuracy of the BCM to measure the variation of the TBW during a fluid challenge of 500 ml of saline during the early phase of septic shock.
Patients suffering from septic shock admitted in our critical care unit for less than 24 hours will be eligible. TBW, ECW and ICW volumes will be measured using the BCM just before (T0), just at the end (T1) and 1 h after the end (T2) of a fluid challenge of 500 ml of saline. Fluid responsiveness will be assessed using trans thoracic echocardiography (TTE). TTE will be performed at T0, T1 and T2. Blood samples will be obtained at T0, T1 and T2 to dose biomarkers of endothelial dysfunction and of capillary leak. The effectiveness of fluid challenge on microcirculation will be investigated by measuring the tissue perfusion index of the urethral mucosa using the IKORUS UP device. Patients will be followed until Day 28 after admission in the critical care unit. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03592693 -
Vitamin C, Hydrocortisone and Thiamine for Septic Shock
|
Phase 2 | |
Terminated |
NCT01639664 -
COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2
|
N/A | |
Withdrawn |
NCT01601938 -
Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients
|
Phase 2 | |
Recruiting |
NCT00335907 -
Protocol-driven Hemodynamic Support for Patients With Septic Shock
|
N/A | |
Completed |
NCT00000574 -
Ibuprofen in Sepsis Study
|
Phase 3 | |
Recruiting |
NCT04910841 -
Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine
|
N/A | |
Active, not recruiting |
NCT04079829 -
Postoperative Respiratory Abnormalities
|
||
Recruiting |
NCT04569942 -
Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
|
Phase 3 | |
Recruiting |
NCT04934943 -
"Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools"
|
||
Completed |
NCT01310790 -
Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock
|
Phase 4 | |
Completed |
NCT00241228 -
Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care)
|
N/A | |
Completed |
NCT00046072 -
A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis
|
Phase 2 | |
Withdrawn |
NCT03122678 -
Thiamine Supplementation in Patients With Septic Shock
|
Phase 1 | |
Recruiting |
NCT06155812 -
Multimodal Vasopressor Strategy in Septic Shock
|
Phase 2/Phase 3 | |
Completed |
NCT04178148 -
Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock
|
N/A | |
Completed |
NCT01453270 -
Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial
|
N/A | |
Completed |
NCT04576819 -
Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis
|
||
Active, not recruiting |
NCT04055909 -
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock
|
Phase 2 | |
Suspended |
NCT03193164 -
Neuromuscular Electrical Stimulation and Septic Shock
|
N/A | |
Completed |
NCT04647552 -
Effects of Hydrocortison Treatment on Angiotensin II and Angiotensin II Receptors in Patients With Septic Shock
|